MADRID, Spain—Even with stringent patient selection and painstaking trial roll-in, macitentan (Actelion) does not appear to be beneficial in patients who have heart failure with preserved ejection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback